<DOC>
	<DOCNO>NCT00185653</DOCNO>
	<brief_summary>The purpose study determine toxicity feasibility non-myeloablative allogeneic hematopoietic cell transplant multiple myeloma unrelated donor .</brief_summary>
	<brief_title>Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma</brief_title>
	<detailed_description>The primary objective protocol evaluate toxicity tolerability mixed chimerism match unrelated donor allogeneic transplant approach patient multiple myeloma . Response , toxicity , survival graft-versus-host disease evaluate .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>) Multiple myeloma responsive therapy . Eligible patient may early relapse disease . Patients must Stage IIIII disease progression initial treatment Stage I disease . Patients relapse follow autologous transplantation may eligible protocol . b ) Age &lt; = 60 year . c ) No prior therapy would preclude use lowdose total body irradiation . ) Patients must pathology review diagnosis confirm Stanford University Medical Center . Patients smolder multiple myeloma , monoclonal gammopathy unknown significance , amyloidosis exclude study . e ) Patients must Karnofsky performance status &gt; 70 % . f ) DLCO &gt; = 60 % predict . g ) ALT AST must &lt; 2X normal . Total bilirubin le 2 mg/dl . h ) Serum creatinine &lt; 2.0 24hour creatinine clearance &gt; = 50 ml/min . ) Patients must HIV negative . j ) Pregnant lactate woman eligible participate . k ) Patients must provide sign , informed consent . ) Severe psychological medical illness b ) Patients undergone prior allogeneic hematopoietic cell transplantation eligible study . c ) Patients HLAidentical sibling donor exclude</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>